Scientists reveal how cancer cells manipulate RNA splicing, increasing tumor growth. A new study introduces antisense ...

Researchers have discovered that cancer cells suppress 'poison exons' -- genetic elements that act as an off switch for protein production -- in a key gene called TRA2 , promoting tumor growth. By ...

Cells have a natural editing system that allows them to rearrange genetic instructions to create different proteins from the ...

Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now that the US Food and Drug Administration (FDA) has lifted a two-year clinical ...

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...

Nearly half of those living with Duchenne who are amenable to exon 44 skipping are adults. ELEVATE-44-102 will provide clinical experience from this important population for our growing data package ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which binds irreversibly to certain mutant forms of ...

Received FDA authorization to initiate ELEVATE-44-102 in the U.S. –– Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. –– ...

Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing ...